94 related articles for article (PubMed ID: 20944678)
21. Elucidating the role of protein kinase C in chronic lymphocytic leukaemia.
Michie AM; Nakagawa R
Hematol Oncol; 2006 Sep; 24(3):134-8. PubMed ID: 16841369
[TBL] [Abstract][Full Text] [Related]
22. Flavopiridol in the treatment of chronic lymphocytic leukemia.
Christian BA; Grever MR; Byrd JC; Lin TS
Curr Opin Oncol; 2007 Nov; 19(6):573-8. PubMed ID: 17906454
[TBL] [Abstract][Full Text] [Related]
23. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
McElligott AM; Maginn EN; Greene LM; McGuckin S; Hayat A; Browne PV; Butini S; Campiani G; Catherwood MA; Vandenberghe E; Williams DC; Zisterer DM; Lawler M
Cancer Res; 2009 Nov; 69(21):8366-75. PubMed ID: 19826055
[TBL] [Abstract][Full Text] [Related]
24. Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocytic leukemia.
Wolowiec D; Ciszak L; Kosmaczewska A; Bocko D; Teodorowska R; Frydecka I; Kuliczkowski K
Haematologica; 2001 Dec; 86(12):1296-304. PubMed ID: 11726322
[TBL] [Abstract][Full Text] [Related]
25. Flavopiridol: where do we stand in chronic lymphocytic leukemia?
Lin TS; Porcu P
Leukemia; 2004 Feb; 18(2):243-6. PubMed ID: 14671637
[No Abstract] [Full Text] [Related]
26. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
Byrd JC; Peterson BL; Gabrilove J; Odenike OM; Grever MR; Rai K; Larson RA;
Clin Cancer Res; 2005 Jun; 11(11):4176-81. PubMed ID: 15930354
[TBL] [Abstract][Full Text] [Related]
27. Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia.
Hutchinson CV; Dyer MJ
Br J Haematol; 2014 Jul; 166(1):12-22. PubMed ID: 24749490
[TBL] [Abstract][Full Text] [Related]
28. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.
Tong WG; Chen R; Plunkett W; Siegel D; Sinha R; Harvey RD; Badros AZ; Popplewell L; Coutre S; Fox JA; Mahadocon K; Chen T; Kegley P; Hoch U; Wierda WG
J Clin Oncol; 2010 Jun; 28(18):3015-22. PubMed ID: 20479412
[TBL] [Abstract][Full Text] [Related]
29. Drugging cell cycle kinases in cancer therapy.
Blagden S; de Bono J
Curr Drug Targets; 2005 May; 6(3):325-35. PubMed ID: 15857291
[TBL] [Abstract][Full Text] [Related]
30. Overview of CDK9 as a target in cancer research.
Morales F; Giordano A
Cell Cycle; 2016; 15(4):519-27. PubMed ID: 26766294
[TBL] [Abstract][Full Text] [Related]
31. Is mTOR inhibition a therapeutic option in chronic lymphocytic leukemia?
Decker T
Leuk Lymphoma; 2008 Dec; 49(12):2235-6. PubMed ID: 19052968
[No Abstract] [Full Text] [Related]
32. A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.
Huang HT; Dobrovolsky D; Paulk J; Yang G; Weisberg EL; Doctor ZM; Buckley DL; Cho JH; Ko E; Jang J; Shi K; Choi HG; Griffin JD; Li Y; Treon SP; Fischer ES; Bradner JE; Tan L; Gray NS
Cell Chem Biol; 2018 Jan; 25(1):88-99.e6. PubMed ID: 29129717
[TBL] [Abstract][Full Text] [Related]
33. Kinase inhibitors in CLL: drawing the roadmap.
Fowler N
Blood; 2021 May; 137(20):2717-2719. PubMed ID: 34014294
[No Abstract] [Full Text] [Related]
34. BMS buys Turning Point Therapeutics and its kinase inhibitors for $4.1 billion.
Mullard A
Nat Rev Drug Discov; 2022 Jul; 21(7):481. PubMed ID: 35681027
[No Abstract] [Full Text] [Related]
35. Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling.
Huber KV; Olek KM; Müller AC; Tan CS; Bennett KL; Colinge J; Superti-Furga G
Nat Methods; 2015 Nov; 12(11):1055-7. PubMed ID: 26389571
[TBL] [Abstract][Full Text] [Related]
36. Optimized chemical proteomics assay for kinase inhibitor profiling.
Médard G; Pachl F; Ruprecht B; Klaeger S; Heinzlmeir S; Helm D; Qiao H; Ku X; Wilhelm M; Kuehne T; Wu Z; Dittmann A; Hopf C; Kramer K; Kuster B
J Proteome Res; 2015 Mar; 14(3):1574-86. PubMed ID: 25660469
[TBL] [Abstract][Full Text] [Related]
37. Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity.
Lemeer S; Zörgiebel C; Ruprecht B; Kohl K; Kuster B
J Proteome Res; 2013 Apr; 12(4):1723-31. PubMed ID: 23495751
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive analysis of kinase inhibitor selectivity.
Davis MI; Hunt JP; Herrgard S; Ciceri P; Wodicka LM; Pallares G; Hocker M; Treiber DK; Zarrinkar PP
Nat Biotechnol; 2011 Oct; 29(11):1046-51. PubMed ID: 22037378
[TBL] [Abstract][Full Text] [Related]
39. Loss of AR-regulated AFF3 contributes to prostate cancer progression and reduces ferroptosis sensitivity by downregulating ACSL4 based on single-cell sequencing analysis.
Fan A; Li Y; Zhang Y; Meng W; Pan W; Chen M; Ma Z; Chen W
Apoptosis; 2024 Mar; ():. PubMed ID: 38478171
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
